Market Overview

UPDATE: Jefferies & Company Reiterates Buy Rating, Lowers PT on Ariad Pharmaceuticals

Related ARIA
Market Wrap For March 28: Markets Still Positive Despite Giving Up Early Gains
Mid-Day Market Update: Restoration Hardware Surges On Earnings; Endocyte Shares Drop

In a report published Monday, Jefferies & Company reiterated its Buy rating on Ariad Pharmaceuticals (NASDAQ: ARIA), but lowered its price target from $27.00 to $23.00.

Jefferies & Company noted, “FDA approves Iclusig in CML/Ph+ ALL pts resistant/intolerant to TKIs, ~3 months earlier (PDUFA date of 3/27/13). Boxed warning on previously undisclosed safety issues (potential liver toxicity, arterial thrombosis) is surprising, although it's hard to know whether these are due to Iclusig, underlying disease, or both given single-arm PACE trial (& 1st-line EPIC interim data comparing ponatinib to imatinib expected ~1H14).”

Ariad Pharmaceuticals closed on Friday at $18.93.

Posted-In: Jefferies & CompanyAnalyst Color Price Target Analyst Ratings

 

Most Popular

Related Articles (ARIA)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free